Seborrheic Dermatitis

The popular atopic dermatitis drug dupilumab has been found to be associated with an increased risk for cutaneous T-cell lymphoma in treated patients. It was the top dermatitis article in dermatology this year.

The National Eczema Association has dedicated October to raising awareness of this inflammatory skin condition, with 2024 focused on reducing stigma using social media.

The Skin of Color Society has released a new educational video series to educate patients, physicians and the general public on dermatologic conditions among individuals with skin of color, according to a press release.

Seborrheic dermatitis is more prevalent across the world than previously believed, with a global pooled prevalence of 4.38%, according to a comprehensive meta-analysis.

Dermatologist Raj Chovatiya, MD, PhD, MSCI, recently spoke to Healio about his new findings in seborrheic dermatitis and how to best treat diverse patient groups with this condition.

Arcutis Biotherapeutics reported Zoryve net sales of $21.6 million in the first quarter of 2024, the company announced in a press release.

Arcutis has entered into a licensing agreement with Sato Pharmaceutical Co. Ltd. to develop, manufacture and commercialize topical roflumilast in Japan for the treatment of multiple skin conditions, according to a company press release.

Phase 3 results that supported the approval of roflumilast foam 0.3% for seborrheic dermatitis treatment showed that the drug was superior to vehicle for individuals aged 9 years and older in this indication, according to a study.

Arcutis has officially launched sales for Zoryve topical foam 0.3% in the U.S. for the treatment of seborrheic dermatitis in individuals aged 9 years and older, according to a press release.

A phase 3 study subgroup analysis showed that patients with seborrheic dermatitis who cannot use topical steroids were more likely to achieve disease clearance with Zoryve topical foam vs. vehicle, Arcutis announced in a press release.